p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. by Walker, C. et al.
Br. J. Cancer (1994). 70, 297 303
1994
p53 expression in normal and dysplastic bronchial epithelium and in lung
carcinomas
C. Walker', L.J. Robertson', M.W. Myskow2, N. Pendleton' & G.R. Dixon2
'Clatterbridge Cancer Research Trust, J K Douglas Cancer Research Laboratory, Clatterbridge Hospital, Bebington, Wirral
L63 4JY, UK; 'Department ofHistopathology, Broadgreen Hospital, Liverpool L14 3LB, UK.
S_mmary Bronchial epithelial dysplasia is thought to be a premalignant stage in the evolution of lung
cancers. Using the CM-1 polyclonal antibody, we have examined the expression of the p53 protein in a larger
series of bronchial dysplasias (n = 60) than hitherto investigated. The p53 protein was detected in 14% ofmild,
25% of moderate and 59% of severe dysplasias; increased p53 expression correlated with the severity of
dysplasia. p53-positive dysplasias had greater PCNA indices than p53-negative dysplasias. p53 expression in
dysplastic tissues was compared with that in two groups of histologically normal epithelium: 14 bronchial
biopsies from non-cancer patients of which all but one were negative and 32 bronchial margins from resecied
carcinomas, of which 17 showed infrequent solitary cells with p53-positive nuclei in predominantly basal
locations scattered throughout the epithelium. These results for resection margins were confirmed by use of a
second antibody, DO-1. Sixty-nine per cent of the corresponding carcinomas were p53 positive, but in 15 cases
the p53 reactivity differed from resection margins. No correlation between p53 expression and any of the
clinicopathological characteristics of these tumours was found. This study supports the observation that
abnormal p53 expression may be an early but not obligatory event in malignant transformation in lung.
Lung cancer remains one of the most common cancers, for
which therapies are currently inadequate and prognosis is
often poor (Souhami. 1992; Richardson & Johnson, 1993).
Improvements in the treatment of this disease would be
greatly assisted by its early detection (Birrer & Brown, 1992).
It is now widely agreed that all lung cancers are derived
from a common pluripotent stem cell capable of expressing a
variety of phenotypes (Mabry et al., 1991). Although the
sequence of events in the histogenesis of lung cancer is
unknown, bronchial epithelial dysplasia is thought to be a
premalignant stage in the evolution of lung carcinomas
(Auerbach et al., 1962. 1979; McDowell et al., 1978). Multi-
step genetic changes, which include activation of cellular
proto-oncogenes and inactivation of tumour-suppressor
genes, are associated with the development of human cancers
and are thought to accompany the morphological changes
that precede malignancy (Minna, 1993).
Currently the most commonly identified genetic change in
human cancers is mutation in the p53 gene (Richardson &
Johnson. 1993), located at position 13 on the short arm of
chromosome 17 (Isobe et al., 1986). This gene is a tumour-
suppressor gene and encodes a 53 kDa nuclear phosphoprotein
capable of binding to DNA and acting as a transcriptional
factor (Finlay, 1993; Minna, 1993). The wild-type p53 pro-
tein inhibits cell proliferation, and loss of this activity leads
to neoplastic transformation (Finlay, 1993; Levine, 1993).
This protein has a short cellular half-life and is usually
present in normal cells, under normal physiological condi-
tions, in extremely small amounts, making it undetectable by
standard immunohistochemical techniques (Iggo et al., 1990;
Rodrigues et al., 1990; Chang et al., 1993). Many mutations
of the p53 gene, principally in exons 5-8 (Hollstein et al.,
1991), lead to a functional inactivation of the -gene and a
protein product unable to regulate transcription, ultimately
resulting in deregulation of cell growth (Chang et al., 1993;
Finlay, 1993; Minna, 1993). Mutant p53 has an extended
cellular half-life enabling immunohistochemical detection of
the accumulated mutant protein in cell nuclei (Levine et al.,
1991). Although not all mutations lead to protein accumula-
tion (Bennett et al., 1991; Lehman et al., 1991; Vahakangas
et al., 1992), in many studies a correlation between the p53
protein detected immunocytochemically and p53 gene muta-
tions has been found (Iggo et al., 1990; Midgely et al., 1992;
Navone et al., 1993). However, recent research has shown
that not all immunohistochemically detected p53 results from
mutation in the p53 gene (Lane, 1992; Wynford-Thomas,
1992; Chang et al., 1993; Fisher et al., 1994). p53 overexpres-
sion has been observed in many malignancies, including
60-70% of lung cancers (Iggo et al., 1990; Soini et al., 1992).
Investigation of p53 overexpression in premalignant tissues
has led to the observations that alterations in the p53 gene
arise as late events in the evolution of some cancers, e.g. in
gastric carcinomas (Joypaul et al., 1993), prostatic car-
cinomas (Navone et al., 1993) or melanomas (Lassam et al.,
1993), whereas in others, e.g. oral (Zhang et al., 1993), gall
bladder (Kamel et al., 1993) and oesophageal (Wang et al.,
1993) malignancies, abnormal p53 expression is a-n early
event. In attempts to define the type and temporal sequence
of somatic genetic changes that precede the onset of invasive
lung cancer, recent studies have reported mutations and
allelic deletions in the p53 gene in preinvasive bronchial
lesions (Sozzi et al., 1992; Sundaresen et al., 1992). Immuno-
detectable p53 has been found in a few cases of bronchial
dysplasia (Vahakangas et al., 1992; Sozzi et al., 1992; Sun-
daresan et al., 1992), and Nuorva et al. (1993) have reported
that p53 overexpression correlated with the severity of dys-
plasia in 17 cases of dysplastic epithelium from cancer-
bearing patients. Thus lesions in the p53 gene have been
reported as possible early events in the development of lung
cancers.
In this study we have investigated the immunohistochem-
ical expression of the p53 protein in a series (n = 60) of
bronchial epithelial dysplasias and related their positivity to
severity of dysplasia and proliferating cell nuclear antigen
(PCNA) indices (Pendleton et al., 1993). p53 expression in
dysplastic tissues was compared with that in histologically
normal bronchial epithelium from non-lung cancer patients
as well as from the resection margins of lung carcinomas.
Expression of p53 in the corresponding tumours was also
investigated.
Materiah and methods
Lung tissues
Sixty formalin-fixed, paraffin-embedded bronchial biopsies
which had been reported to contain dysplastic epithelium
were retrieved from the archives at the Histopathology
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Department. Broadgreen Hospital, Liverpool. In 45 cases
there was a concomitant diagnosis of lung cancer. Ten cases
were either associated with a benign lesion or did not have
any other form of pulmonary pathology. Clinical data were
not available for the remaining five cases. Dysplasia was
graded independently by two pathologists as mild, moderate
or severe as described in Pendleton et al. (1993). Fourteen
formalin-fixed, paraffin-embedded bronchial biopsies, taken
from patients who did not have lung cancer at the time of
biopsy and which contained epithelium reported as histolog-
ically normal, were also obtained from the files. Thirty-two
formalin-fixed. paraffin-embedded specimens of lung carci-
noma and their corresponding bronchial resection margins
were collected prospectively by N. Pendleton from lobec-
tomies or pneumonectomies performed at the Cardiothoracic
Centre, Liverpool, UK. Patients received no other form of
therapy either prior to or following surgery and were staged
using UICC guidelines. Full clinical data were available for
these cases.
Immunohistochemistrv
p53 immunoreactivity was determined using methods essen-
tially similar to those descnrbed by Green et al. (1993). Five
micron sections were cut, mounted on glass and dried over-
night at 37°C. prior to dewaxing in xylene for 20 min and
rehydration through alcohol. Endogenous peroxidase was
destroyed by incubation in methanol containing 3% hydro-
gen peroxide (v/v) for 20 min. Sections were washed in water
then immersed in Tris-buffered saline (TSB), pH 7.6, contain-
ing 0.1% bovine serum albumin (BSA) (Sigma cat. no. A-
4503). This buffer was used for all subsequent washes and for
dilution of antibodies. Sections were incubated with primary
antibody for 30 min at 20°C, either the polyclonal antibody
CM-1 (Novacastra) at 1:800 or the monoclonal antibody
DO-1 (Ab-6) (Oncogene Science) at 1:100. These antibodies
recognise both wild-type and mutant forms of p53 (Midgely
et al., 1992; Vojtesek et al., 1992). After three washes in
buffer. biotinylated swine anti-rabbit (Dako code no. E413)
or biotinylated rabbit anti-mouse (Dako code no. E431)
secondary antibodies were applied at dilutions of 1:300 and
sections incubated for 30 min at 20°C. After three washes in
buffer, staining was visualised by the avidin-biotin-peroxi-
dase technique (Dako code no. 355), followed after three
washes by incubation in phosphate-citrate buffer, pH 6.4,
containing 0.05% 3',3-diaminobenzidine tetrahydrochloride
and 0.3% hydrogen peroxide. After 5 min, the sections were
washed in water, counterstained in haematoxylin, dehydrated
and mounted in DPX mounting medium. Negative controls
using normal swine serum for polyclonals and normal rabbit
serum for monoclonals at 1:400 and TBS instead of the
primary antibody were included in each staining run. Cos
monkey cells transfected with the p53 oncogene were used as
positive controls and were a gift from Dr J. Jenkins, Marie
Cure Institute, UK.
Approximate percentages of nuclei that were p53 positive
in normal or dysplastic epithelium and p53-positive tumour
nuclei in carcinomas were assessed and scored as follows: 0,
negative; 1, <10%; 2, 10-50%; 3, > 50%. The intensity of
staining in p53-positive nuclei was compared with the
positive control and scored as follows: 0, negative; 1, clearly
stained but with an intensity less than the positive control; 2,
intensity equal to the positive control; 3, intensity greater
than the positive control. The overall p53 score for each
section was the sum of the distribution and the intensity
scores. In some cases cytoplasmic staining was present; this
was noted, but only nuclear staining was considered positive.
PCNA indices of dysplastic biopsies and resection margins
had been determined previously (Pendleton et al., 1993); in
this study, these results were related to p53 reactivity.
Statistical analysis
The significances of associations were determined using
Fisher-Irwin's exact probability test. Mann-Whitney tests
were used to compare PCNA indices for p53-positive and
p53-negative groups. Spearman's rank correlation was used
to compare severity of dysplasia with degree of p53 expres-
sion, and the Mann-Whitney test used to compare p53
expression between tissue groups. Survival data for p53-
positive versus p53-negative tumours were analysed using the
Peto log-rank test. Two-tailed probabilities are quoted for all
statistical tests.
Results
p53positivity in normal and dvsplastic bronchial epithelium
p53 immunoreactivity was investigated using the CM-1
antibody in biopsies of normal and dysplastic bronchial
epithelium. Twenty-eight of the 60 dysplastic biopsies were
p53 positive compared with only one of the 14 normal
bronchial biopsies taken from patients who did not have
cancer at the time of biopsy (Table I).
In seven of the biopsies tumour was present in the same
section as dysplastic epithelium; in five the p53 reactivity of
tumour cells and dysplastic epithelium was in agreement, but
in two cases dysplastic epithelium was p53 positive although
adjacent tumour was negative.
p53positivity andgrade ofdysplasia
Of the biopsies investigated, dysplasia was mild in seven
cases, moderate in 12 cases and severe in 41 cases. Using the
CM-1 antibody, cells with clearly stained p53-positive nuclei
were found in 14% of the mild, 25% of the moderate and
59% of the severe dysplasias (Figure 1 and Table II). In the
one case of mild dysplasia found to be p53 positive, positive
nuclei were present in <1% of the epithelial cells and were
located basally and suprabasally scattered along the
epithelium. In moderate and severe dysplasias, p53-positive
cells were seen in basal and suprabasal layers, although in
some cases these cells were present throughout the full thick-
ness of the epithelium (Figure 1). p53-positive cells were
frequently intensely stained and often present as foci of
positive cells.
Table I p53 positivity in normal and dysplastic epithelium in
bronchial biopsies
p53 Normal Dysplasia Total
Negative 13 32 45
Positive 1 28 29
Total 14 60 74
P = 0.006, Fisher-Irwin exact test (two-tailed).
Figwe 1 p53 immunoreactivity in severely dysplastic epithelium.
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p53 expression was found to correlate with the severity of
dysplasia. p53 was detected significantly more often in severe
dysplasias than in mild + moderate dysplasias or mild dys-
plasias (Table II). Significant differences between normal and
dysplastic epithelium were only found when the severe dys-
plasias were included in the group analysed. Compared with
normal epithelium p53 expression was significantly greater in
all dysplasias (Table I), severe dysplasias and in moderate
+ severe dysplasias (Table II).
p53 score andgrade ofdvsplasia
The system of p53 scoring used in these experiments (Table
III) permitted a semiquantitative comparison of the degree of
p53 expression in the various tissues examined. With increas-
ing severity of dysplasia there was not only an increase in the
percentage of cases demonstrating p53 staining but also an
increase in the staining intensity of positive cells and an
increase in the proportions of these positive cells. Thus,
higher grades of dysplasia were associated with higher p53
scores; the Spearman rank correlation coefficient for the
whole table (Table III) is 0.47 (P = <0.0001), and consider-
ing just the dysplasia cases it is 0.37 (P = 0.002). Comparison
of p53 expression between the various grades of dysplasia by
use of p53 score as in Table III results in more significant
P-values by the Mann-Whitney test than obtained with the
Fisher-Irwin tests of Table II.
PCNA indices
For 39 cases of bronchial dysplasia, PCNA indices had been
determined previously (Pendleton et al., 1993). p53-positive
dysplasias had significantly greater PCNA indices than p53-
negative dysplasias (Table IVa), indicating abnormal growth
in these p53-positive biopsies.
Bronchial carcinomas and resection margins
In previous studies, a series of bronchial carcinomas (Burnett
et al., 1993) and their corresponding resection margins which
contained histologically normal epithelium (Pendleton et al.,
1993) had been collected prospectively following surgery.
Using the CM-1 antibody, p53-positive nuclei were seen in
22/32 (69%) of the tumours and in histologically normal
epithelium in 17/32 (53%) of the resection margins (Table V).
p53-positive cells in resection margins were predominantly
basal, solitary and scattered throughout the epithelium
(Figure 2a), and were less frequent than in tumour tissues
(Figure 2b) or many samples of dysplastic epithelium. Many
nuclei were weakly stained, but some showed a staining
intensity similar to p53-positive tumour cells. Compared with
dysplasias and tumour tissues the p53 scores of resection
margins were low (Tables III and V), with only one case with
a score of 3 and no higher scores. To confirm these results,
sections of resection margins were stained with the mono-
clonal antibody DO-1; all of the cases positive for the CM-1
antibody were also DO-1 positive, but two cases (numbers 16
and 21) which were negative for CM-1 were clearly positive
for DO-1.
Clearly stained p53-positive nuclei were significantly more
often detected in histologically normal epithelium from the
bronchial resection margins of lung cancer patients than in
the normal bronchial epithelium from patients who did not
have cancer (P= 0.003, Fisher-Irwin test). PCNA indices
(Pendleton et al., 1993) of p53-positive resection margins did
not differ significantly from the p53-negative group (Table
IVb).
The p53 scores for positive tumours were generally higher
than the scores for normal or dysplastic epithelium (Tables
III and V), indicating an increased level of p53 expression in
tumours. p53-positive tumour nuclei were frequently intens-
ely stained (Figure 2b) and often showed a patchy distribu-
tion within the tumour. In some cases p53 positivity was
focal, and in some it was observed at the leading edge of the
tumour. Because of the focal distribution of p53 positivity in
Table I p53 positivity and grade of dysplasia
Histology
Dysplasia
p53 NVormal Mild Moderate Severe Total
Negative 13 6 9 17 45
Positive 1 1 3 24 29
Total 14 7 12 41 74
Fisher-Irwin exact test (two-tailed probabilities): mild versus
severe, 0.04; moderate versus severe, NS; mild + moderate versus
severe, 0.01; mild versus normal, NS; moderate versus normal, NS,
severe versus normal. 0.001: moderate + severe versus normal. 0.004;
NS. not significant.
Table III p53 score
Histology
D)ysplasia
p53 score Normal MUild Moderate Severe Total
0 13 6 9 17 45
2 1 1 1 8 11
3-4 0 0 2 11 13
5-6 0 0 0 5 5
Total 14 7 12 41 74
P-values by Mann-Whitney test (two-tailed): mild versus severe,
0.03: moderate versus severe, 0.05; mild + moderate versus severe,
0.005.
Table IV PCNA indices
PCNA index
Number
of cases Median Range p
(a) Dvsplastic bronchial epithelium
p53 negative 22 10 0-88
p53 positive 17 71 2-94 00001
(b) Normal epithelium in resection margins
p53 negative 15 5 0-15
p53 positive 17 0 0-19 NS
'Two-tailed Mann-Whitney test. NS, not significant.
tumours, the need to examine multiple blocks has been
reported (Soini et al., 1992; Nuorva et al., 1993). In this
study, 20/32 of the tumours were p53 positive when one
block from each case was examined. For every negative case,
a further 2-4 blocks were investigated. This resulted in only
two additional positive cases (tumour no. 10, for which two
blocks were positive and one was negative, and tumour
no. 21, for which two blocks were positive and two were
negative).
Seven out of 11 (64%) adenocarcinomas, 10/15 (66%)
squamous cell carcinomas, 1/1 small-cell-lung cancer (SCLC),
1/2 bronchial carcinoids, 1/1 large-cell carcinoma, 1/1 adeno-
squamous and 1/1 squamous/SCLC had immunodetectable
p53. There was no significant difference in p53 expression in
adenocarcinomas and squamous cell carcinomas. No correla-
tion between p53 expression and tumour stage, TNM score
or patient survival was found.
In 15 cases the p53 reactivity in the tumour differed from
that found in the normal epithelium in corresponding resec-
tion margins; in ten cases the tumour was positive for p53
while the resection margins were negative; and in five cases
the tumour was p53 negative although the normal epithelium
contained p53-positive cells.
This study has investigated the immunohistochemical expres-
sion of the p53 protein in a larger single series of bronchial
dysplasias than hitherto investigated (Sozzi et al., 1992; Sun-300 C. WALKER et al.
Table V Expression of p53 in bronchial carcinomas and resection margins
Normal epithelium
Carcinomas in resection margins
p53 p53 p53 p53 p53 p53
Case distribution intensity overall distribution intensity overall
No. Histology score score score score score score
State I
I Adenocarcinoma 3 3 6 1 1 2
2 Adenocarcinoma 1 1 2 0 0 0
3 Squamous cell 3 3 6 0 0 0
4 Squamous cell 3 3 6 0 0 0
5 Squamous cell 0 0 0 1 1 2
6 Adenocarcinoma 0 0 0 1 1 2
7 Carcinoid 1 1 2 1 1 2
State II
8 Adenocarcinoma 2 2 4 1 1 2
9 Squamous cell 2 1 3 1 1 2
10 Squamous cell 2 2 4 1 2 3
11 Large cell 3 2 5 0 0 0
12 Adenocarcinoma 0 0 0 0 0 0
13 Carcinoid 0 0 0 0 0 0
14 Squamous cell 2 2 4 0 0 0
15 Squamous cell 3 2 5 1 1 2
16 Squamous cell 3 2 5 0 0 0
Stage IIIa
17 Adenocarcinoma 3 2 5 1 1 2
18 Squamous cell 3 2 5 1 1 2
19 Adenol'squamous 2 2 4 0 0 0
20 Squamous cell 3 2 5 0 0 0
21 Adenocarcinoma 1 1 2 0 0 0
22 Adenocarcinoma 1 1 2 1 1 2
23 Small cell 3 2 5 1 1 2
24 Squamous cell 0 0 0 1 1 2
25 Squamous cell 0 0 0 1 1 2
26 Adenocarcinoma 1 2 3 1 1 2
27 Squamous/small cell 3 2 5 0 0 0
28 Adenocarcinoma 0 0 0 1 1 2
29 Adenocarcinoma 0 0 0 0 0 0
30 Squamous cell 0 0 0 0 0 0
31 Squamous cell 0 0 0 0 0 0
32 Squamous cell 3 3 6 1 1 2
daresan et al., 1992; Vahakangas et al., 1992; Nuorva et al.,
1993) and supports the conclusion that p53 overexpression
correlates significantly with severity of bronchial dysplasia.
Detection of the p53 protein in mild and moderate dysplasias
suggests that abnormal p53 expression is an early event in
the malignant transformation process in lung; these results
support the observations that somatic genetic changes in the
p53 gene occur in preinvasive lesions of the lung (Sundaresan
et al., 1992; Vahakangas et al., 1992).
During the course of the preparation of this manuscript,
Bennett et al. (1993), also using the CM-1 antibody in a
series of 34 cases, have reported that the p53 protein
accumulates frequently in early bronchial neoplasia. Our
study supports their conclusions but differs in that biopsies,
not resected tumours, were examined and all tissues were
derived from a single treatment centre. Combining the results
of our study with those of other published studies (Sozzi et
al., 1992; Sundaresan et al., 1992; V.hakangas et al., 1992;
Bennett et al., 1993; Nuorva et al., 1993), p53 expression has
so far been investigated in a combined total of 23 mild, 31
moderate and 77 severe dysplasias. Provided that assessment
ofpositivity is similar in all studies, 19% of the mild, 28% of
the moderate and 63% of the severe dysplasias have been
found to be p53 positive.
In other similar studies investigating the expression of the
p53 protein in premalignant lesions of lung (Bennett et al.,
1993; Nuorva et al., 1993) and other tissues (Joypaul et al.,
1993; Kamel et al., 1993), results were analysed by assess-
ment of p53 positivity. In this study, analysis was either by
comparison ofp53-positive and -negative groups or by use of
a p53 scoring system similar to that described by Vojtesk et
al. (1993). The advantage of this scoring system is that it
allows comparison of the degree of p53 expression between
tissue groups. The p53-positive group, equivalent to the
positive group in other similar studies, had a p53 score of
two or more. Cells with the p53 score for intensity of 1 were
clearly p53 positive and were found in tumours as well as in
dysplasias and normal tissues.
Unlike other studies of preinvasive lung lesions (Sozzi et
al., 1992; Sundaresan et al., 1992; Vihaikangas et al., 1992;
Bennett et al., 1993; Nuorva et al., 1993), PCNA indices for
many of the dysplasias in this series had been determined
(Pendleton et al., 1993). The greater PCNA indices of the
p53-positive group indicates that p53-positive dysplasias con-
tain higher proportions of cells in the proliferative phase of
the cell cycle; this suggests that p53-positive dysplasias may
have abnormalities in their growth control mechanisms. It is
possible that alterations in the p53 gene confer a growth
advantage on these cells, leading to expansion ofp53-positive
cells as severity of dysplasia increases. A close relation
between p53 overexpression and PCNA indices has also been
observed in pancreatic duct cell carcinomas (Suzuki &
Takano, 1993), hepatocellular carcinomas (Saegusa et al.,
1993) and gastric cancers (Yonemura et at., 1993).
In this study, p53 expression in dysplastic tissues was
compared with two groups of histologically normal epithe-
lium. All but one of the first group, taken from patients who
did not have cancer at the time of biopsy, were negative.
Comparison of p53 expression in this group with that in
dysplastic bronchial biopsies showed a highly significant
difference between these groups. The second group of his-
tologically normal epithelium analysed, from the resection
margins of bronchial carcinomas, showed p53-positive cells
in a high proportion of cases, indicating differences in the
normal bronchial epithelium of cancer and non-cancer
patients. The patient from whom the one p53-positive biopsy
of normal bronchial epithelium was obtained did not develop
lung cancer in 9 months following biopsy.p53 IN BRONCHIAL EPITHELIUM AND CARCINOMAS 301
a
Fugwe 2 p53 immunoreactivity (a) in a resection margin from a
squamous cel carcinoma showing nuclear staing in a few cells
scattered along the epithehum (scale bar = 10 m), and (b) in a
squamous cell carcioma showing strong nuclear staining in a
high proportion of tumour cells (scale bar=20pm).
The intensity and distribution of p53-positive cells in his-
tologically normal epithelium was similar to that observed in
the one case ofmild dysplasia found to be p53 positive. In all
but one case, the intensity of p53-positive nuclei was scored
as 1. These results reflect genuine p53 overexpression in these
cells and are not experimental artefact because: (a) a second
antibody showed similar results, (b) a high proportion of
resection margins contained p53-positive cells and (c) these
cells, although often weakly stained and infrequently dis-
tributed, were clearly evident against a background of p53-
negative epithelial and mesenchymal tissues. Similar p53
positivity was found in 3/6 histologially normal cells in
oesophageal epithelium (Wang et al., 1993), and VWhikangas
et al. (1992) commented that occasional p53-positive normal-
appearing bronchial mucosal cells were observed in the nor-
mal tissues adjacent to a lung tumour from a uranium miner.
Bennett et al. (1993) have reported that all 22 examples of
normal mucosa examined in their series from bronchial resec-
tions were p53 negative, although four cases were reported to
have 'equivocal' stain.
It has recently been observed that not all immunodetec-
table p53 reacts with antibodies speii for the mutant form
(Fontanini et al., 1993; Rubio et al., 1993) or is associated
with mutation in the p53 gene (Vihakangas et al., 1992;
Campbell et al., 1993; Marchetti et al., 1993; Rubio et al.,
1993; Vojtesek & Lane, 1993). Elevated amounts ofwild-type
p53 are found in cells in a variety of circumstances, e.g. in
cells undergoing DNA repair, in which accumulation of the
p53 protein mediates arrest in the GI phase of the cell cycle,
or in association with abnormal levels of viral or cellular
proteins known to bind to the p53 protein, such as the SV40
large T antigen or the MDM2 gene product (Lane, 1992;
Bennett et al., 1993; Chang et al., 1993; Levine, 1993). Thus
p53 overexpression detected by immunocytochemistry may
reflect not gene mutation but some post-translational mech-
anism.
p53 positivity in the normal mucosa of resection margins
did not result in a measurable increase in proliferation, as
indicated by PCNA indices. This may suggest that the
mechanism whereby the p53 protein is elevated in normal
mucosa differs from that in dysplasia. Whatever the mech-
anism to account for these p53-positive cells in normal bron-
chial mucosa, it seems that their presence, even if not
associated with mutation in the p53 gene, indicates abnor-
malities that are not reflected in the histological appearance
of these cells. Cytogenetic abnormalities and overexpression
of p62-myc, epidermal growth factor receptor (EGFR) and
HER-2/neu have also been observed in histologically normal
epithelium from the resection margins of lung cancer patients
(Som et al., 1991; Sundaresan et al., 1991), suggesting that
cytogenetic instability or misregulation of normal growth
controls precedes morphological change and may be early
events in the transition from normal epithelium to invasive
cancer. Such changes may contribute to the mechanism
whereby lung cancer patients have an increased tendency
towards the formation of a second primary lung cancer
(Som et al., 1991). p53 abnormality in normal and dysplastic
tissues was not necessarily associated with p53 overexpression
in tumours. Such results suggest that early lesions in the p53
gene are only one of a number of such genetic alterations
which, following further multiple and complex genetic
changes, lead to the formation of a carcinoma.
The number of p53-positive tumours in the series (69%
overall and 68% for non-small-cell lung cancers) agreed well
with the incidence of p53 positivity for lung cancers reported
in some studies (Iggo et al., 1990; Fontanini et al., 1993;
Marchetti e al., 1993) but was higher than that found in
others (Quinlan et al., 1992; Soini et al., 1992). Although the
number of tumours in this series was smalL no correlation in
p53 overexpression was found with any ofthe clnical charac-
teristics of these tumours. This contrasts with reports of a
relationship between p53 overexpression and poor prognosis
and shortened survival (Quinlan et al., 1992; Horio et al.,
1993), tumour grade (Soini et al., 1992) or lymph node
involvement (Fontanini et al., 1993; Marchetti et al., 1993)
and a greater inadence in squamous cell carcinomas com-
pared with other types of lung carcinoma (Iggo et at., 1990;
Soini et al., 1992). Further investigation of a larger series of
tumours from this geographical region would be necesary to
relate p53 positivity to clnicopathological features of the
diseas as presented in Merseyside.
This study supports the observation that abnormal p53
expression is an early but not obligatory event in the evolu-
tion oflung cancers. Immunodetection ofp53 overexpression
in bronchial epithelium may be a useful tool in the
identification of those early lesions which may progress to
malignancy.
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